CNTX — Context Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareMicro Cap
Context Therapeutics Q2 net loss widens on higher R&D costs
Context Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76
Brief: Context Therapeutics Enters Into License Agreement Amendment With BioAtla For CT-202
Context Therapeutics Q1 net loss widens on higher R&D costs
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Context Therapeutics rises as FDA grants fast-track status to ovarian cancer drug
Brief: Context Therapeutics Reports Full Year 2025 Operating And Financial Results
Advisory: Alert from Equity-Insider.com was published in error and has been withdrawn
Context Therapeutics Q3 net loss narrows to $9.7 mln
Brief: Context Therapeutics Amends Sales Deal, May Sell Up To $75 Million in Common Stock – SEC Filing
Brief: Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule
Context Therapeutics Q2 net loss widens, cash funds ops into 2027
Brief: Context Therapeutics To Appoint Dr. Karen Chagin, M.D. As Chief Medical Officer
Brief: Context Therapeutics Doses First Patient In Phase 1 Clinical Trial Of Ct-95
Brief: Context Therapeutics Reports Full Year 2024 Operating And Financial Results
Brief: Context Therapeutics Says First Patient Dosed In The Phase 1 Clinical Trial Of CTIM-76
Brief: Context Therapeutics Appoints Andy Pasternak As Chairman Of The Board Of Directors